Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD7 universal chimeric antigen receptor T cell therapy - Gracell Biotechnology

Next Previous
Drug Profile

Anti-CD7 universal chimeric antigen receptor T cell therapy - Gracell Biotechnology

Alternative Names: Anti-CD7 U-CAR-T Cell Therapy - Gracell Biotechnology; CD7 UCAR-T cells

Latest Information Update: 28 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gracell Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in China (Parenteral, Infusion)
  • 22 Feb 2024 Gracell Biotechnology has been acquired by AstraZeneca
  • 11 Feb 2020 Anti-CD7 universal chimeric antigen receptor T cell therapy - Gracell Biotechnology is available for licensing as of 11 Feb 2020. https://www.gracellbio.com/

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top